Novo Nordisk ASMEX:NOVOBN +3.85%79 Dividend Yield % is 4.09% as of Jun. 24, 2026, which is 102% above its 10-year median of 2.02. GuruFocus rates MEX:NOVOBN with a GF Score™ of 79/100 and a GF Value™ of MXN2,387.36 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 515 Drug Manufacturers companies, Novo Nordisk AS ranks better than 77.86% on this metric.
As of today (2026-06-24), the Trailing Annual Dividend Yield of Novo Nordisk AS is 4.09%.
The historical rank and industry rank for Novo Nordisk AS's Dividend Yield % or its related term are showing as below:
MEX:NOVOBN'
s Dividend Yield % Range Over the Past 10 Years
Min: 0.78 Med: 2.02 Max: 5.1
Current: 4.09
During the past 13 years, the highest Dividend Yield of Novo Nordisk AS was 5.10%. The lowest was 0.78%. And the median was 2.02%.
MEX:NOVOBN's Dividend Yield % is ranked better than 77.86% of 515
companies
in the Drug Manufacturers industry
Industry Median: 2.02
vs MEX:NOVOBN: 4.09
During the past 12 months, Novo Nordisk AS's average Dividends Per Share Growth Rate was 2.60% per year.
During the past 3 years, the average Dividends Per Share Growth Rate was 27.80% per year.
During the past 5 years, the average Dividends Per Share Growth Rate was 23.80% per year.
During the past 10 years, the average Dividends Per Share Growth Rate was 12.90% per year.
During the past 13 years, the highest 3-Year average Dividends Per Share Growth Rate of Novo Nordisk AS was 37.70% per year. The lowest was -30.80% per year. And the median was 15.80% per year.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.
Novo Nordisk AS (MEX:NOVOBN) Dividend Yield % Explanation
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
The historical data trend for Novo Nordisk AS's Dividend Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:NOVOBN vs LLY, JNJ, ABBV: Dividend Yield % Comparison
For the Drug Manufacturers - General subindustry, Novo Nordisk AS's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Novo Nordisk AS Dividend Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Novo Nordisk AS's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Novo Nordisk AS's Dividend Yield % falls into.
Dividend Yield measures how much a company pays out in dividends each year relative to its share price.
Novo Nordisk AS Recent Full-Year* Dividend History
Amount
Ex-date
Record Date
Pay Date
Type
Frequency
Forex Rate
DKK 7.950000
2026-03-30
2026-03-30
2026-03-31
Cash Dividend
semi-annually
DKK:MXN 2.778609
DKK 3.750000
2025-08-18
2025-08-18
2025-08-19
Cash Dividend
semi-annually
DKK:MXN 2.928489
* GuruFocus has an internal rule that if the most recent dividend payment frequency is at least 4 times a year, then the full year will be calculated according to the frequency of payment or the one-year time frame, whichever is stricter.
* GuruFocus converts dividend currency to local traded share price currency in order to calculate dividend yield. Please refer to the last column "Forex Rate" in the above table.
Novo Nordisk AS's Trailing Annual Dividend Yield (%) for Today is calculated as
Trailing Annual Dividend Yield
=
Most Recent Full Year Dividend
/
Current Share Price
=
33.0717753
/
810.00
=
4.08 %
Current Share Price is MXN810.00. Novo Nordisk AS's Dividends per Share for the trailing twelve months (TTM) ended in Today is MXN33.0717753.
Novo Nordisk AS's Forward Annual Dividend Yield (%) for Today is calculated as
Forward Annual Dividend Yield
=
Forward Full Year Dividend
/
Current Share Price
=
44.1798831
/
810.00
=
5.45 %
Current Share Price is MXN810.00. Novo Nordisk AS's Dividends per Share for the forward twelve months is calculated as MXN22.08994155 * 2 = MXN44.1798831.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Novo Nordisk AS (MEX:NOVOBN) has a Dividend Yield % of 4.09% as of Jun. 24, 2026. Dividend yield is the ratio of company dividends to the share price. View historical data on Novo Nordisk AS and its competitors. This is 102% above median its historical median of 2.02. Over the past decade, Novo Nordisk AS's Dividend Yield % has ranged from 0.78 to 5.10. According to the industry distribution chart, Novo Nordisk AS ranks #114 out of 515 companies in the Drug Manufacturers industry, placing it in the top 22.1%.
Is Novo Nordisk AS's Dividend Yield % too high?
Novo Nordisk AS's current Dividend Yield % of 4.09% is 102% above median its 10-year median of 2.02. Over the past 10 years, this metric has ranged from a low of 0.78 to a high of 5.10. The Drug Manufacturers industry median Dividend Yield % is 2.02. Novo Nordisk AS's value of 4.09% is 102.5% above this industry median. Based on the distribution chart, Novo Nordisk AS ranks #114 out of 515 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Novo Nordisk AS has a GF Score™ of 79/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Novo Nordisk AS's Dividend Yield % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Novo Nordisk AS ranks #114 out of 515 companies for Dividend Yield %. This places Novo Nordisk AS in the top 22% of its industry — outperforming the majority of peers. The industry median Dividend Yield % is 2.02. Novo Nordisk AS's value of 4.09% is 102.5% above this benchmark. Historically, Novo Nordisk AS's own Dividend Yield % has ranged from 0.78 to 5.10 over the past decade. While the company's 10-year median is 2.02 vs. the industry median of 2.02, Novo Nordisk AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Yield % for a Drug Manufacturers company?
The median Dividend Yield % among Drug Manufacturers companies is 2.02, based on 515 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Novo Nordisk AS's current Dividend Yield % of 4.09% is 102.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Yield % mean?
A high Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Dividend yield is the ratio of company dividends to the share price. View historical data on Novo Nordisk AS and its competitors. For the Drug Manufacturers industry, the median Dividend Yield % is 2.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Novo Nordisk AS's current Dividend Yield % is 4.09%, which is 102% above median its own 10-year median of 2.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novo Nordisk AS stock overvalued right now?
Based on GuruFocus' analysis, Novo Nordisk AS (MEX:NOVOBN) is currently considered Significantly Undervalued. The stock's GF Value™ is MXN2,387.36, compared to a current price of MXN810.00 — trading 66.1% below its estimated fair value. The current Dividend Yield % is 4.09%, which is 102% above median its 10-year median of 2.02 and 102.5% above the Drug Manufacturers industry median of 2.02. Novo Nordisk AS's overall GF Score™ is 79/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Yield % calculated?
Dividend Yield % is calculated from a company's financial statements. For Novo Nordisk AS (MEX:NOVOBN), the current Dividend Yield % is 4.09% as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Novo Nordisk AS (MEX:NOVOBN) Overvalued in 2026?
Based on GuruFocus' analysis, Novo Nordisk AS stock appears to be undervalued.
The current stock price of MXN810.00 is trading 66.1% below its estimated GF Value™ of MXN2,387.36.
GuruFocus considers Novo Nordisk AS to be Significantly Undervalued.
Key valuation signals for MEX:NOVOBN:
Dividend Yield %: 4.09% (102% above median its 10-year median of 2.02)
GF Value™: MXN2,387.36 vs. price of MXN810.00 (66.1% below fair value)
Industry Position: 102.5% above the Drug Manufacturers median (#114 of 515)
No single metric tells the full story. See the MEX:NOVOBN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
79GF Score
Get the complete analysis for MEX:NOVOBN
Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:NOVOBN has been successfully added to your 
